Home › Calculator › BIIB Dividend Calculator 2026
BIIB Dividend DRIP Calculator 2026
0.92% YieldHealthcareBiogen Inc. · NASDAQ
Price: $218.50 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BIIB pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your BIIB snowball 📈
$10,000 in BIIB → $1.6K in 10 years · $10.19/month
About Biogen Inc. (BIIB) — Dividend Analysis 2026
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Compare BIIB with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BIIB DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BIIB position with:
🌍 BIIB Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BIIB.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.92% | -1.88% | $92 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.78% | -2.02% | $78 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.74% | -2.06% | $74 / yr |
| 🇬🇧 UK ISA | 0% | 0.92% | -1.88% | $92 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.84% | -1.96% | $84 / yr |
| 🇨🇦 TFSA | 0% | 0.92% | -1.88% | $92 / yr |
| 🇨🇦 CA Taxable | 25% | 0.69% | -2.11% | $69 / yr |
| 🇦🇺 Super (pension) | 15% | 0.78% | -2.02% | $78 / yr |
| 🇦🇺 AU Taxable | 30% | 0.64% | -2.16% | $64 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.68% | -2.12% | $68 / yr |
| 🇫🇷 FR Taxable | 30% | 0.64% | -2.16% | $64 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BIIB Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BIIB Dividend Payment Schedule
BIIB pays quarterly — 4 times per year. Next ex-div: TBD.
📊 BIIB vs Healthcare Benchmarks
How BIIB compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BIIB sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BIIB Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-09-01 | 7,405 | — | — | ||
| Sale | 2026-08-03 | 593 | $203.34 | $120.6K | ||
| Sale | 2026-08-04 | 593 | $200.96 | $119.2K | ||
| A-Award | 2026-06-09 | 1,505 | — | — | ||
| A-Award | 2026-06-09 | 1,505 | — | — | ||
| A-Award | 2026-06-09 | 1,505 | — | — | ||
| A-Award | 2026-06-09 | 1,505 | — | — | ||
| A-Award | 2026-06-09 | 1,505 | — | — | ||
| A-Award | 2026-06-09 | 1,505 | — | — | ||
| A-Award | 2026-06-09 | 1,505 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where BIIB earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BIIB dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Biogen Inc. (BIIB) is currently trading at $218.50, 37% below its 52-week high. The current dividend yield is 0.92% based on an annual payout of $2.00 per share.
BIIB (Biogen Inc.) — 0.92% Dividend Yield Analysis
Biogen Inc. (BIIB) is a healthcare stock currently trading at $218.50 with a dividend yield of 0.92%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.